June 9, 2017 / 4:03 PM / a year ago

Johnson & Johnson expects to complete of Actelion offer on June 16

ZURICH (Reuters) - Johnson & Johnson (JNJ.N) said Friday’s approval of its proposed acquisition of Swiss biotech company Actelion ATLN.S by the European Commission meant all regulatory approvals required to complete the $30 billion deal have been received.

The U.S. company said it expects settlement of the all-cash public tender offer by its Swiss subsidiary, Janssen Holding, on June 16.

EU antitrust regulators approved on Friday Johnson & Johnson’s planned purchase of Actelion subject to conditions intended to ensure clinical development of insomnia drugs were unaffected.

Reporting by John Revill; editing by Brenna Hughes Neghaiwi

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below